Bio News
Developing a next-generation bispecific antibody targeting gamma-delta T cells Lead candidate CYT-X300 slated for clinical trials in EGFR-positive solid tumors
UK biotech company Cytospire has raised $83 million in a Series A financing. The funds will be used to develop CYT-X300, a bispecific antibody targeting EGFR-positive solid tumors that harnesses gamma-delta T cells. The company plans to conduct clinical trials of CYT-X300 in colorectal cancer, head and neck cancer, and other indications.
Biobook Team
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
